GlassScriptPhysician profile
Eryn Gorman
NPI 1710430632
$17,609.38
in general payments reported to CMS, 2019-2025
42 companies · $792 in 2025
The $792 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,389 · 2022: $5,923 · 2023: $3,975 · 2024: $2,530 · 2025: $792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,266 · Education: $31.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,266.34 |
| Education | $31.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,811.07 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Corcept Therapeutics | $2,206.49 | 2021-2025 | Korlym |
| Insulet Corporation | $1,920.59 | 2021-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $1,237.46 | 2021-2025 | |
| Lilly USA, LLC | $1,150.13 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $954.42 | 2021-2025 | Repatha, Tepezza, Evenity |
| Astrazeneca Pharmaceuticals LP | $806.83 | 2021-2022 | |
| Dexcom, INC. | $784.68 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Alexion Pharmaceuticals, INC. | $694.18 | 2022-2024 | Strensiq |
| Medtronic, INC. | $631.07 | 2021-2024 | Minimed 780g, Inpen Smart Insulin Delivery System, Intellis Adaptivestim |
| Xeris Pharmaceuticals, INC. | $463.11 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Abbott Laboratories | $453.09 | 2021-2023 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $437.53 | 2022-2025 | |
| Esperion Therapeutics, INC. | $413.20 | 2021-2024 | Nexletol |
| Abbvie INC. | $307.77 | 2021-2024 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.69 | 2022-2024 | Jardiance |
| Radius Health, INC. | $235.12 | 2022-2025 | Tymlos |
| Antares Pharma, INC. | $203.20 | 2021-2024 | Xyosted, Tlando, Nocdurna |
| Recordati_rare_diseases_inc. | $187.22 | 2021-2024 | Isturisa |
| Sanofi-Aventis U.S. LLC | $180.45 | 2021-2024 | |
| Tandem Diabetes Care, INC. | $157.32 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Cequr Corporation | $144.23 | 2023-2024 | Cequr Simplicity |
| Merck Sharp & Dohme LLC | $123.69 | 2021-2022 | |
| Lifescan, INC. | $113.95 | 2021-2023 | |
| Ibsa Pharma INC. | $97.63 | 2022-2024 | Tirosint, Licart, Tirosint |
| Mannkind Corporation | $96.81 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $91.37 | 2021-2024 | Unithroid |
| Eusa Pharma (US) LLC | $63.03 | 2022 | |
| Amarin Pharma, INC. | $58.39 | 2021-2022 | |
| Zealand Pharma US, INC. | $56.67 | 2021 | |
| Halozyme INC | $41.30 | 2023 | |
| Kyowa Kirin, INC. | $39.90 | 2023-2024 | Crysvita |
| Currax Pharmaceuticals LLC | $39.71 | 2022 | |
| Ascensia Diabetes Care US INC. | $24.91 | 2021 | |
| Madrigal Pharmaceuticals | $19.64 | 2024 | Resmetirom |
| Regeneron Healthcare Solutions, INC. | $19.31 | 2024 | Evkeeza |
| Endo Pharmaceuticals INC. | $19.31 | 2022 | |
| Exact Sciences Corporation | $18.85 | 2025 | Cologuard Collection Kit |
| Beta Bionics, INC. | $17.97 | 2024 | Ilet Bionic Pancreas |
| Astellas Pharma US INC | $17.09 | 2023 | Veozah |
| Avvisto Therapeutics, LLC | $15.51 | 2025 | Cycloset |
| Clarus Therapeutics INC. | $9.49 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eryn Gorman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.